More supply for AtCor
Wednesday, 08 October, 2008
AtCor Medical [ASX: ACG] has signed an agreement to supply its SphygmoCor systems and clinical trial support services to an international pharmaceutical company.
The contract is worth at least US$930,000 [AUD$1.3 million], and has brought to US$3.7 million [AUD$5.2 million] the total value of pharmaceutical trial contracts secured by AtCor in the past 130 days.
SphygmoCor visibly identifies the effects of reflected blood pressure in the central aortic wave. This measure can't be detected with standard blood pressure monitoring.
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
Free meningococcal B vaccines coming to the NT
The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
